pcDNA3.1/ZMYM2-FGFR1
(Plasmid
#167486)
-
PurposeMammalian expression vector for the ZMYM2-FGFR1 fusion gene associated with myeloid and lymphoid neoplasms
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 167486 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepcDNA3.1
-
Backbone manufacturerInvitrogen
- Backbone size w/o insert (bp) 5427
- Total vector size (bp) 9497
-
Vector typeMammalian Expression
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameZMYM2-FGFR1
-
Alt nameZNF198-FGFR1
-
SpeciesH. sapiens (human)
-
Insert Size (bp)4075
-
GenBank IDNM_003453.6 NM_023110.3
-
Entrez GeneFGFR1 (a.k.a. BFGFR, CD331, CEK, ECCL, FGFBR, FGFR-1, FLG, FLT-2, FLT2, HBGFR, HH2, HRTFDS, KAL2, N-SAM, OGD, bFGF-R-1)
-
Entrez GeneZMYM2 (a.k.a. FIM, MYM, NECRC, RAMP, SCLL, ZNF198)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site BamHl (not destroyed)
- 3′ cloning site BamHl (not destroyed)
- 5′ sequencing primer T7
- 3′ sequencing primer BGH (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pcDNA3.1/ZMYM2-FGFR1 was a gift from Nicholas Cross (Addgene plasmid # 167486 ; http://n2t.net/addgene:167486 ; RRID:Addgene_167486) -
For your References section:
ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5. Smedley D, Demiroglu A, Abdul-Rauf M, Heath C, Cooper C, Shipley J, Cross NC. Neoplasia. 1999 Oct;1(4):349-55. doi: 10.1038/sj.neo.7900035. 10.1038/sj.neo.7900035 PubMed 10935490